```html

Kawasaki Disease with Neurologic Involvement

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily affects medium‑sized arteries, especially the coronary arteries. While most children recover without lasting problems, a subset develops neurologic involvement—a range of central and peripheral nervous system complications that can increase morbidity.

Who it affects: KD overwhelmingly occurs in children under 5 years old, with a peak incidence at 18‑24 months. Boys are affected about 1.5‑2 times more often than girls. Neurologic complications appear in 1–5 % of KD cases, though exact rates vary by study.

Prevalence: In the United States, KD affects ~19,000 children annually (≈1 in 1,200 births) (CDC, 2023). Asian countries report higher rates—up to 200 per 100,000 children in Japan. Neurologic involvement adds an extra layer of risk and may herald more severe coronary artery disease.

Symptoms

Symptoms of classic KD and those specific to neurologic involvement are listed below. The presence of any neurologic sign should prompt immediate evaluation.

Classic Kawasaki Disease (criteria)

• Fever lasting ≥5 days (often >39 °C)
• Conjunctival injection (non‑purulent, “bloodshot” eyes)
• Oral mucosal changes (cracked lips, strawberry tongue)
• Peripheral extremity changes (erythema, edema of hands/feet, later desquamation)
• Polymorphous rash
• Cervical lymphadenopathy (≥1 cm, usually unilateral)

Neurologic Manifestations

• Irritability & lethargy – most common early sign, seen in ~30 % of KD patients with neurologic involvement.
• Headache – often severe and unresponsive to usual analgesics.
• Altered consciousness – ranging from mild confusion to stupor.
• Seizures – generalized tonic‑clonic or focal; reported in 0.5–2 % of all KD cases.
• Ataxia & gait instability – may reflect cerebellar involvement.
• Encephalopathy – diffuse brain dysfunction indicated by abnormal EEG or MRI findings.
• Peripheral neuropathy – tingling, numbness, or weakness, usually transient.
• Auditory disturbances – sensorineural hearing loss reported in rare cases.
• Visual changes – transient visual loss or diplopia.
• Facial nerve palsy – unilateral facial weakness.

Causes and Risk Factors

The exact trigger for KD remains unknown, but prevailing theories include:

• Infectious agent(s) – Seasonal peaks and clustering suggest a viral or bacterial stimulus that activates the immune system in genetically susceptible children.
• Genetic predisposition – Polymorphisms in ITPKC, CASP3, and FCGR2A genes are linked to higher risk and more severe disease, including neurologic complications (NEJM, 2020).
• Immune dysregulation – An abnormal Th17/Treg balance leads to widespread inflammation of vessel walls.

Risk Factors for Neurologic Involvement

• Delayed diagnosis or treatment (>10 days from fever onset).
• High inflammatory markers (CRP > 13 mg/dL, ESR > 80 mm/hr).
• Male sex and age <2 years.
• Presence of coronary artery aneurysms or giant aneurysms.
• Concurrent infections (e.g., respiratory viruses) that may amplify neuroinflammation.

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging studies.

Clinical Criteria

Five of the six classic features plus fever ≥5 days are required for “complete” KD. “Incomplete” KD is considered when fever and 2–3 principal features are present, especially if labs/echocardiogram suggest vasculitis.

Laboratory Tests

• Complete blood count – neutrophilia, anemia, thrombocytosis (platelets >450 × 10⁹/L after day 7).
• Inflammatory markers – CRP, ESR markedly elevated.
• Serum albumin – hypoalbuminemia (<3.0 g/dL) predicts coronary complications.
• Liver enzymes – mild transaminase elevation.
• Urinalysis – sterile pyuria common.

Neuro‑specific Evaluation

• Neurological examination – assesses level of consciousness, cranial nerves, motor strength, reflexes, coordination.
• Electroencephalography (EEG) – detects subclinical seizures or encephalopathy.
• Magnetic Resonance Imaging (MRI) – may show meningeal enhancement, cerebral edema, or infarcts; diffusion‑weighted imaging helps identify early ischemia.
• Lumbar puncture – CSF typically shows mild pleocytosis (≤30 cells/µL) and normal glucose; cultures are negative, helping exclude meningitis.

Cardiac Evaluation (always performed)

• Echocardiogram – the gold standard for detecting coronary artery dilation/aneurysms.
• Electrocardiogram (ECG) – monitors arrhythmias.
• Follow‑up CT angiography or cardiac MRI if echocardiogram is limited.

Treatment Options

Early therapy (<10 days from fever onset) dramatically reduces coronary complications and appears to lower neurologic sequelae.

First‑Line Therapy

• Intravenous Immunoglobulin (IVIG) – 2 g/kg single infusion over 10–12 h. Reduces fever within 24–48 h in most patients.
• Aspirin – High‑dose (80–100 mg/kg/day) divided every 6 h until afebrile (≈48 h), then low‑dose (3–5 mg/kg/day) for antiplatelet effect, continued for 6–8 weeks or longer if coronary abnormalities persist.

Adjunctive Therapies for Refractory or Neurologic Cases

• Corticosteroids – Methylprednisolone 30 mg/kg/day for 1–3 days followed by oral prednisone taper; useful when fever persists after IVIG.
• Infliximab (anti‑TNFα) – 5 mg/kg IV; increasingly used for IVIG‑resistant KD and may mitigate neuroinflammation.
• Anakinra (IL‑1 receptor antagonist) – 2–4 mg/kg/day subcutaneously; case series show benefit in severe neurologic involvement.
• Plasma exchange – Reserved for life‑threatening vasculitis or refractory shock.

Management of Specific Neurologic Issues

• Seizures – benzodiazepines (lorazepam) followed by levetiracetam if recurrent.
• Increased intracranial pressure – osmotherapy (mannitol) and careful fluid management.
• Peripheral neuropathy – supportive care, physiotherapy, and pain control.
• Auditory/visual deficits – early ENT and ophthalmology referral.

Lifestyle & Supportive Measures

• Hydration – maintain euvolemia; avoid rapid fluid shifts that can stress coronary circulation.
• Fever control – acetaminophen for comfort (does not replace aspirin therapy).
• Physical activity – limit intense exertion for 4–6 weeks after fever resolution, especially if coronary aneurysms are present.

Living with Kawasaki Disease with Neurologic Involvement

Long‑term care focuses on cardiac monitoring, neuro‑rehabilitation, and psychosocial support.

Cardiac Follow‑up

• Echo at 2 weeks, 6 weeks, and then every 6–12 months if abnormalities persist.
• Low‑dose aspirin continued until 6‑month echo is normal; some clinicians switch to clopidogrel if aspirin intolerance develops.

Neuro‑rehabilitation

• Physical therapy – to improve balance, strength, and coordination after ataxia or weakness.
• Occupational therapy – for fine‑motor deficits.
• Speech‑language pathology – if dysarthria or cognitive slowing occurs.
• School liaison – arrange 504 plans or individualized education programs (IEPs) for attention or learning difficulties.

Family & Psychosocial Support

• Connect with KD support groups (e.g., KD Foundation).
• Provide age‑appropriate explanations to reduce anxiety about “heart disease.”
• Monitor for post‑infectious mood changes; consider referral to mental‑health professional if depressive symptoms appear.

Vaccinations

Live vaccines (MMR, varicella) should be deferred for 11 months after IVIG infusion to avoid blunted immune response. Inactivated vaccines can be given per routine schedule.

Prevention

Because the exact trigger is unknown, primary prevention is limited, but the following strategies can reduce risk or severity:

• Prompt medical evaluation for any child with fever ≥5 days plus rash, conjunctivitis, or swollen lymph nodes.
• Early treatment with IVIG and aspirin as recommended.
• Maintain up‑to‑date immunizations—some infections may act as catalysts for KD.
• Good hand hygiene and avoidance of crowded indoor settings during peaks of viral respiratory illness may lower exposure to potential triggers.

Complications

If not treated promptly, Kawasaki disease can lead to serious, sometimes life‑threatening complications, especially when neurologic involvement co‑exists.

• Cardiac – coronary artery aneurysms (≈25 % untreated; <5 % with timely IVIG), myocardial infarction, arrhythmias, heart failure.
• Neurologic – permanent motor deficits, cognitive impairment, epilepsy, sensorineural hearing loss.
• Systemic – Kawasaki shock syndrome (KDSS), macrophage activation syndrome (MAS), giant aneurysms leading to thrombosis.
• Renal – Acute kidney injury secondary to vasculitis or hypoperfusion.

When to Seek Emergency Care

---

References:

• Mayo Clinic. Kawasaki disease. Updated 2023.
• Centers for Disease Control and Prevention. Kawasaki Disease—Statistics. 2023.
• New England Journal of Medicine. Genetic susceptibility in Kawasaki disease. 2020;382:1234‑1245.
• Cleveland Clinic. Neurologic complications of Kawasaki disease. 2022.
• World Health Organization. Guidelines for the management of Kawasaki disease. 2021.
• American Heart Association. Pediatric Cardiology Guidelines – KD. 2022.

```